Treatment of acute lymphoblastic leukemia (ALL) is associated with neurocognitive deficits in young children. While computerized measures have been utilized in pediatric oncology research, they exclude patients below the age of 4 years. Patients enrolled on “Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents” were offered participation in an optional neurocognitive study. Three-year old patients did not differ from 4-year-old patients in their ability to perform or complete the tests. Including patients diagnosed at age 3 will serve to improve our understanding of at-risk patients and their neurocognitive trajectory both during and after treatment.
© 2025 Cogstate Ltd.
Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.